Syndax Pharmaceuticals (SNDX) Equity Average (2016 - 2025)
Historic Equity Average for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Q3 2025 value amounting to $136.4 million.
- Syndax Pharmaceuticals' Equity Average fell 6592.6% to $136.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.4 million, marking a year-over-year decrease of 6592.6%. This contributed to the annual value of $421.2 million for FY2024, which is 1755.26% down from last year.
- According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Equity Average is $136.4 million, which was down 6592.6% from $186.2 million recorded in Q2 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Equity Average peaked at $523.0 million during Q1 2024, and registered a low of $136.4 million during Q3 2025.
- Its 5-year average for Equity Average is $341.0 million, with a median of $368.2 million in 2022.
- Its Equity Average has fluctuated over the past 5 years, first soared by 46444.44% in 2021, then crashed by 6592.6% in 2025.
- Syndax Pharmaceuticals' Equity Average (Quarter) stood at $303.7 million in 2021, then surged by 32.63% to $402.8 million in 2022, then grew by 13.39% to $456.7 million in 2023, then decreased by 28.34% to $327.3 million in 2024, then tumbled by 58.31% to $136.4 million in 2025.
- Its Equity Average stands at $136.4 million for Q3 2025, versus $186.2 million for Q2 2025 and $251.6 million for Q1 2025.